Puma Biotechnology Inc. (PBYI) announced Wednesday that the FDA's Oncologic Drugs Advisory Committee voted 12 - 4 to recommend approval of PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer.
from RTT - Before the Bell http://ift.tt/2rCA0AA
via IFTTT
No comments:
Post a Comment